Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.
Beta-blocker
Cardiogenic shock
Catecholamine
Heart failure
Levosimendan
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
29 Nov 2019
29 Nov 2019
Historique:
received:
22
07
2019
accepted:
14
11
2019
entrez:
1
12
2019
pubmed:
1
12
2019
medline:
6
5
2020
Statut:
epublish
Résumé
Despite interesting and unique pharmacological properties, levosimendan has not proven a clear superiority to placebo in the patient populations that have been enrolled in the various recent multicenter randomized controlled trials. However, the pharmacodynamic effects of levosimendan are still considered potentially very useful in a number of specific situations.Patients with decompensated heart failure requiring inotropic support and receiving beta-blockers represent the most widely accepted indication. Repeated infusions of levosimendan are increasingly used to facilitate weaning from dobutamine and avoid prolonged hospitalizations in patients with end-stage heart failure, awaiting heart transplantation or left ventricular assist device implantation. New trials are under way to confirm or refute the potential usefulness of levosimendan to facilitate weaning from veno-arterial ECMO, to treat cardiogenic shock due to left or right ventricular failure because the current evidence is mostly retrospective and requires confirmation with better-designed studies. Takotsubo syndrome may represent an ideal target for this non-adrenergic inotrope, but this statement also relies on expert opinion. There is no benefit from levosimendan in patients with septic shock. The two large trials evaluating the prophylactic administration of levosimendan (pharmacological preconditioning) in cardiac surgical patients with poor left ventricular ejection fraction could not show a significant reduction in their composite endpoints reflecting low cardiac output syndrome with respect to placebo. However, the subgroup of those who underwent isolated CABG appeared to have a reduction in mortality. A new study will be required to confirm this exploratory finding.Levosimendan remains a potentially useful inodilator agent in a number of specific situations due to its unique pharmacological properties. More studies are needed to provide a higher level of proof regarding these indications.
Identifiants
pubmed: 31783891
doi: 10.1186/s13054-019-2674-4
pii: 10.1186/s13054-019-2674-4
pmc: PMC6883606
doi:
Substances chimiques
Cardiotonic Agents
0
Simendan
349552KRHK
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
385Références
Anesthesiology. 2014 May;120(5):1098-108
pubmed: 24614322
Med Intensiva. 2018 Oct;42(7):409-415
pubmed: 29126662
J Cardiothorac Vasc Anesth. 2013 Dec;27(6):1224-32
pubmed: 24050857
N Engl J Med. 2017 May 25;376(21):2021-2031
pubmed: 28320259
Br J Anaesth. 2016 Jul;117(1):52-8
pubmed: 27317704
JAMA. 2017 Aug 8;318(6):548-556
pubmed: 28787507
J Appl Physiol (1985). 2007 Nov;103(5):1888-93
pubmed: 17641217
Int J Cardiol. 2014 Jul 15;175(1):55-61
pubmed: 24820737
Intensive Care Med. 2011 Apr;37(4):701-10
pubmed: 21380525
Ann Intensive Care. 2019 Feb 1;9(1):24
pubmed: 30707314
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Cardiovasc Pharmacol. 2004 Apr;43(4):555-61
pubmed: 15085067
Eur Heart J. 2018 Jun 7;39(22):2047-2062
pubmed: 29850820
Am J Cardiol. 2006 Dec 1;98(11):1489-92
pubmed: 17126656
Int J Cardiol. 2016 Jan 1;202:138-43
pubmed: 26386941
Biochem Pharmacol. 2004 Sep 1;68(5):807-12
pubmed: 15294443
Herz. 2008 Jul;33(5):368-73
pubmed: 18773157
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2009 Mar;11(3):304-11
pubmed: 19158152
Circulation. 2003 Jun 24;107(24):2998-3002
pubmed: 12821585
Anesthesiology. 2013 Jun;118(6):1460-5
pubmed: 23511607
Eur Heart J. 2011 Aug;32(15):1838-45
pubmed: 21388993
JACC Heart Fail. 2019 Feb;7(2):174
pubmed: 30704607
Ann Emerg Med. 2009 Dec;54(6):811-817.e1-3
pubmed: 19766354
Crit Care Med. 2007 Aug;35(8):1948-54
pubmed: 17568324
ASAIO J. 2013 Nov-Dec;59(6):554-7
pubmed: 24172260
Eur J Heart Fail. 2016 Jan;18(1):8-27
pubmed: 26548803
J Card Fail. 2007 Sep;13(7):556-9
pubmed: 17826646
J Cardiovasc Pharmacol. 2012 May;59(5):441-9
pubmed: 22240915
Clin Pharmacol Ther. 1997 May;61(5):596-607
pubmed: 9164421
Eur J Pharmacol. 1997 Nov 19;339(1):97-100
pubmed: 9450621
J Mol Cell Cardiol. 1995 Oct;27(10):2155-65
pubmed: 8576932
Crit Care Med. 2007 May;35(5):1376-82
pubmed: 17414729
J Thorac Cardiovasc Surg. 2019 Jun 21;:null
pubmed: 31358329
N Engl J Med. 2017 May 25;376(21):2032-2042
pubmed: 28316276
J Pharm Pharmacol. 2000 Feb;52(2):213-7
pubmed: 10714952
Intensive Care Med. 2019 Oct;45(10):1392-1400
pubmed: 31428804
Int J Cardiol. 2016 Sep 1;218:150-157
pubmed: 27232927
Anesthesiology. 1999 Nov;91(5):1318-28
pubmed: 10551583
Br J Anaesth. 2009 Feb;102(2):198-204
pubmed: 19151048
Eur Heart J Suppl. 2018 Dec;20(Suppl I):I11-I20
pubmed: 30555280
J Cardiovasc Pharmacol. 2012 Nov;60(5):450-5
pubmed: 22932705
Crit Care Med. 2009 Dec;37(12):3017-23
pubmed: 19661807
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2769-78
pubmed: 24814488
J Cardiothorac Vasc Anesth. 2016 Dec;30(6):1449-1453
pubmed: 27495966
Eur J Heart Fail. 2010 Apr;12(4):404-10
pubmed: 20335355
Eur J Pharmacol. 1997 Aug 27;333(2-3):249-59
pubmed: 9314042
N Engl J Med. 2016 Oct 5;375(17):1638-1648
pubmed: 27705084
Intensive Care Med. 2011 Feb;37(2):290-301
pubmed: 21086112
Lancet. 2002 Jul 20;360(9328):196-202
pubmed: 12133653
J Card Surg. 2015 Jul;30(7):547-54
pubmed: 25989324
Eur J Heart Fail. 2014 Aug;16(8):898-906
pubmed: 24920349
Anesthesiology. 2008 Jun;108(6):979-87
pubmed: 18497597
Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669
pubmed: 29376560
Crit Care Med. 2006 Nov;34(11):2814-9
pubmed: 16971854
J Mol Cell Cardiol. 1995 Sep;27(9):1859-66
pubmed: 8523447
Circulation. 2017 Oct 17;136(16):e232-e268
pubmed: 28923988
Eur J Heart Fail. 2007 Jan;9(1):75-82
pubmed: 16829185
Circulation. 2000 Oct 31;102(18):2222-7
pubmed: 11056096
Eur Heart J Suppl. 2017 Mar;19(Suppl C):C8-C14
pubmed: 29249905
Eur J Heart Fail. 2018 Jul;20(7):1128-1136
pubmed: 29405611
Pulm Circ. 2018 Jul-Sep;8(3):2045894018790905
pubmed: 29979110
Heart. 2006 Dec;92(12):1768-72
pubmed: 17105880
JAMA. 2001 Jan 10;285(2):190-2
pubmed: 11176812
Crit Care Med. 2012 Feb;40(2):634-46
pubmed: 21963578
J Biol Chem. 1994 Nov 18;269(46):28584-90
pubmed: 7961805
Int J Clin Pharmacol Ther. 2002 Oct;40(10):465-71
pubmed: 12395979
Eur Heart J. 2002 Sep;23(18):1422-32
pubmed: 12208222
J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2112-2119
pubmed: 29748076
JAMA. 2007 May 2;297(17):1883-91
pubmed: 17473298
Eur Heart J Suppl. 2017 Mar;19(Suppl C):C2-C7
pubmed: 29249904
Ann Intensive Care. 2015 Dec;5(1):52
pubmed: 26152849
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002230
pubmed: 15674893